Literature DB >> 31933888

Celastrol inhibits colon cancer cell proliferation by downregulating miR-21 and PI3K/AKT/GSK-3β pathway.

Haoliang Ni1, Yuejun Han1, Xihan Jin1.   

Abstract

Celastrol is a traditional Chinese medicine, that is derived from Tripterygium wilfordii. It has been proposed to offer anti-tumor potential. MicroRNAs also play important roles in tumorigenesis. However, the anti-tumor mechanism of Celastrol and whether miRNAs are involved in the process are still unknown. In the present study, MTT assay was used to test the IC50 of Celastrol and cell viability. PCNA, PI3K, Akt, GSK3β, phosphorylated Akt and GSK3β were measured by western blotting. Flow cytometry was introduced to detect the apoptosis. We found Celastrol inhibited colon cancer cell viability in a dose-dependent manner companied with PCNA downregulation. Apoptosis was induced by Celastrol. After Celastrol treatment, BCL-2 expression decreased while BAX increased and the Caspase-3 activity was induced. Simultaneously, miR-21 expression was reduced in Celastrol-treated colon cancer cells. miR-21 mimic overexpression could enhance the cell viability, inhibit the apoptosis, decrease BCL-2 expression, increase BAX and induce Caspase-3 activity to some extent which were reversed by Celastrol. In addition, the PI3K/AKT/GSK-3β pathway was activated by miR-21 mimic but partially arrested by extra-adding Celastrol. Thus, Celastrol may inhibit colon cancer cell proliferation by negatively regulating miR-21 and the PI3K/AKT/GSK-3β pathway. IJCEP
Copyright © 2019.

Entities:  

Keywords:  Akt; Celastrol; colon cancer; miR-21; proliferation

Year:  2019        PMID: 31933888      PMCID: PMC6945181     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 2.  From traditional Chinese medicine to rational cancer therapy.

Authors:  Thomas Efferth; Paul C H Li; Venkata S Badireenath Konkimalla; Bernd Kaina
Journal:  Trends Mol Med       Date:  2007-07-17       Impact factor: 11.951

3.  Celastrol inhibits breast cancer cell invasion via suppression of NF-ĸB-mediated matrix metalloproteinase-9 expression.

Authors:  Yoonseo Kim; Hyereen Kang; Sung-Wuk Jang; Jesang Ko
Journal:  Cell Physiol Biochem       Date:  2011-08-16

4.  Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA‑21 and the suppression of the PI3K/Akt‑NF‑κB signaling pathway in an in vitro model of ovarian carcinoma.

Authors:  Haiyan Zhang; Jianhua Li; Guang Li; Surong Wang
Journal:  Mol Med Rep       Date:  2016-10-26       Impact factor: 2.952

5.  Up-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with Coptidis rhizoma aqueous extract.

Authors:  Meifen Zhu; Ning Wang; Sai-Wah Tsao; Man-Fung Yuen; Yigang Feng; Thomas S K Wan; Kwan Man; Yibin Feng
Journal:  Exp Ther Med       Date:  2010-11-19       Impact factor: 2.447

Review 6.  Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease.

Authors:  A C Allison; R Cacabelos; V R Lombardi; X A Alvarez; C Vigo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2001-10       Impact factor: 5.067

7.  Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells.

Authors:  Lisa B Frankel; Nanna R Christoffersen; Anders Jacobsen; Morten Lindow; Anders Krogh; Anders H Lund
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

Review 8.  Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.

Authors:  Ashok Kumar Pandurangan
Journal:  Asian Pac J Cancer Prev       Date:  2013

9.  MiR-155-5p controls colon cancer cell migration via post-transcriptional regulation of Human Antigen R (HuR).

Authors:  Amr Al-Haidari; Anwar Algaber; Raed Madhi; Ingvar Syk; Henrik Thorlacius
Journal:  Cancer Lett       Date:  2018-02-20       Impact factor: 8.679

10.  Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice.

Authors:  Sophie Kusy; Eliver E B Ghosn; Leonore A Herzenberg; Christopher H Contag
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

View more
  7 in total

1.  Celastrol Inhibited Human Esophageal Cancer by Activating DR5-Dependent Extrinsic and Noxa/Bim-Dependent Intrinsic Apoptosis.

Authors:  Xihui Chen; Shiwen Wang; Li Zhang; Shuying Yuan; Tong Xu; Feng Zhu; Yanmei Zhang; Lijun Jia
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

Review 2.  Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors.

Authors:  Argyro Papadopetraki; Maria Maridaki; Flora Zagouri; Meletios-Athanasios Dimopoulos; Michael Koutsilieris; Anastassios Philippou
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

Review 3.  Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer.

Authors:  Zeinab Moafian; Abolfazl Maghrouni; Arash Soltani; Seyed Isaac Hashemy
Journal:  Mol Biol Rep       Date:  2021-05-31       Impact factor: 2.316

Review 4.  Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals.

Authors:  Seung Wan Son; Han Yeoung Lee; Sokviseth Moeng; Hyo Jeong Kuh; Soo Young Choi; Jong Kook Park
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

Review 5.  MicroRNA-21 Is a Versatile Regulator and Potential Treatment Target in Central Nervous System Disorders.

Authors:  Xue Bai; Zhigang Bian
Journal:  Front Mol Neurosci       Date:  2022-01-31       Impact factor: 5.639

6.  The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification.

Authors:  Jiaoyu Yi; Mengran Tian; Linfei Hu; Ning Kang; Weike Ma; Jingtai Zhi; Xiangqian Zheng; Xianhui Ruan; Ming Gao
Journal:  Ann Transl Med       Date:  2021-05

7.  Identification of Putative Non-Substrate-Based XT-I Inhibitors by Natural Product Library Screening.

Authors:  Thanh-Diep Ly; Anika Kleine; Bastian Fischer; Vanessa Schmidt; Doris Hendig; Joachim Kuhn; Cornelius Knabbe; Isabel Faust
Journal:  Biomolecules       Date:  2020-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.